Obesity Discussion Forums - View Single Post - Amylin Pharms expands clinical program in obesity

Obesity Discussion · 10-26-06, 03:37 PM

Market Report -- In Play (AMLN)

All Briefing News
Amylin Pharms expands clinical program in obesity Co announces extensive program of clinical trials which will assess the safety and efficacy of multiple neurohormones used in combination to treat obesity. Co says this integrated approach to obesity therapy is based on extensive clinical experience with the analog of the human hormone, amylin, called pramlintide, and preclinical data combining neurohormones. Results presented today from a Phase 2 extension study demonstrate that patients completing 52 weeks of pramlintide therapy experienced a 7-8% mean body weight reduction compared to a 1% reduction in patients receiving placebo. Also, co says preclinical data were presented revealing novel, additive and synergistic weight loss effects when amylin is used in combination with other neurohormones.

Obesity Program Expansion

10-26-06, 03:37 PM	#1 (permalink)
Obesity Discussion Administrator Join Date: Jan 2005 Location: Phoenix, AZ Posts: 7,874 Weight Statistics 8/1/2006 Start Date: 185 lb Start Weight: 152 lb Current Weight: 155 lb Goal Weight: -33 lb Weight Loss: 5/1/2007 Goal Date:	Amylin Pharms expands clinical program in obesity Market Report -- In Play (AMLN) All Briefing News Amylin Pharms expands clinical program in obesity Co announces extensive program of clinical trials which will assess the safety and efficacy of multiple neurohormones used in combination to treat obesity. Co says this integrated approach to obesity therapy is based on extensive clinical experience with the analog of the human hormone, amylin, called pramlintide, and preclinical data combining neurohormones. Results presented today from a Phase 2 extension study demonstrate that patients completing 52 weeks of pramlintide therapy experienced a 7-8% mean body weight reduction compared to a 1% reduction in patients receiving placebo. Also, co says preclinical data were presented revealing novel, additive and synergistic weight loss effects when amylin is used in combination with other neurohormones. Obesity Program Expansion __________________